Sugi Predict

Sugi Predict / Compounds / SCHEMBL29570254

SCHEMBL29570254

SCHEMBL29570254

CO[C@H]1CCN(c2nc(=O)n(-c3ccccc3)c3cc(Cl)ccc23)C1

nearest known ligand 0.76

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 19/20 0.76
▸ MAT1A Q00266 1/20 0.76
▸ PRMT5 O14744 2/20 0.53
▸ CYP1A2 P05177 1/20 0.49
▸ MAOB P27338 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22103485 1.00 MAT2A (0.76) MAT2AMAT1APRMT5CYP1A2MAOB
SCHEMBL23548999 1.00 MAT2A (0.76) MAT2AMAT1APRMT5CYP1A2MAOB
SCHEMBL22103471 1.00 MAT2A (0.76) MAT2AMAT1APRMT5CYP1A2MAOB
SCHEMBL29570085 1.00 MAT2A (0.76) MAT2AMAT1APRMT5CYP1A2MAOB
SCHEMBL29570365 1.00 MAT2A (0.76) MAT2AMAT1APRMT5CYP1A2MAOB
SCHEMBL23583456 0.88 MAT2A (0.79) MAT2AMAT1APRMT5CYP1A2
SCHEMBL22093249 0.86 MAT2A (1.00) MAT2AMAT1APRMT5
SCHEMBL22093247 0.86 MAT2A (1.00) MAT2AMAT1APRMT5
SCHEMBL29569856 0.86 MAT2A (1.00) MAT2AMAT1APRMT5
SCHEMBL23549022 0.85 MAT2A (0.82) MAT2AMAT1APRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 — — US disclosed
US-12115163-B2 Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor IDEAYA BIOSCIENCES, INC. (US) 2024-10-15 — — US disclosed
US-20240269143-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR GLAXOSMITHKLINE LLC 2024-08-15 — — US disclosed
US-20240173326-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. 2024-05-30 — — US disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173326-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR PRMT1, PRMT6, MAT2A MAT2A 3/4885MAT1A 11/4885PRMT5 5/4885
US-20240269143-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR PRMT1, PRMT6, MNAT1 MAT2A 7/4885MAT1A 11/4885PRMT5 5/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A MAT2A 2/4885MAT1A 3/4885PRMT5 72/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MAT2A 2/4885MAT1A 3/4885PRMT5 72/4885
US-12115163-B2 Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor PRMT1, PRMT6, MAT2A MAT2A 3/4885MAT1A 11/4885PRMT5 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.